select a format

Single User License
USD 2000 INR 128240
Site License
USD 4000 INR 256480
Corporate User License
USD 6000 INR 384720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Epithelial Ovarian Cancer-Pipeline Review, H2 2015

Epithelial Ovarian Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC7214IDB
  • |
  • Pages: 450
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Epithelial Ovarian Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Epithelial Ovarian Cancer-Pipeline Review, H2 2015', provides an overview of the Epithelial Ovarian Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Epithelial Ovarian Cancer Overview 11

Therapeutics Development 12

Pipeline Products for Epithelial Ovarian Cancer-Overview 12

Pipeline Products for Epithelial Ovarian Cancer-Comparative Analysis 13

Epithelial Ovarian Cancer-Therapeutics under Development by Companies 14

Epithelial Ovarian Cancer-Therapeutics under Investigation by Universities/Institutes 20

Epithelial Ovarian Cancer-Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Epithelial Ovarian Cancer-Products under Development by Companies 24

Epithelial Ovarian Cancer-Products under Investigation by Universities/Institutes 30

Epithelial Ovarian Cancer-Companies Involved in Therapeutics Development 31

AbbVie Inc. 31

Acceleron Pharma, Inc. 32

Adaptimmune Limited 33

Amgen Inc. 34

Ascenta Therapeutics, Inc. 35

Astex Pharmaceuticals, Inc. 36

AstraZeneca Plc 37

Bayer AG 38

Bionomics Limited 39

BioNumerik Pharmaceuticals, Inc. 40

Boehringer Ingelheim GmbH 41

Caladrius Biosciences, Inc. 42

Celldex Therapeutics, Inc. 43

Celon Pharma Sp. z o.o. 44

Celsion Corporation 45

Cerulean Pharma, Inc. 46

Clovis Oncology, Inc. 47

Dr. Reddy's Laboratories Limited 48

EirGenix Inc. 49

Eisai Co., Ltd. 50

Eli Lilly and Company 51

Epirus Biopharmaceuticals, Inc. 52

Exelixis, Inc. 53

F. Hoffmann-La Roche Ltd. 54

Genentech, Inc. 55

Genor BioPharma Co., Ltd. 56

Glycotope GmbH 57

Hetero Drugs Limited 58

ImmunoGen, Inc. 59

Immunotope, Inc. 60

Incyte Corporation 61

Innate Immunotherapeutics Limited 62

Johnson & Johnson 63

Mabion SA 64

MabVax Therapeutics Holdings, Inc. 65

MedImmune, LLC 66

Merck & Co., Inc. 67

Millennium Pharmaceuticals, Inc. 68

Mycenax Biotech Inc. 69

Novartis AG 70

Oasmia Pharmaceutical AB 71

OBI Pharma, Inc. 72

Oncobiologics, Inc. 73

Oncolytics Biotech Inc. 74

Otsuka Holdings Co., Ltd. 75

Oxford BioMedica Plc 76

OXiGENE, Inc. 77

Pfizer Inc. 78

Pharma Mar, S.A. 79

Pharmacyclics, Inc. 80

Prima BioMed Ltd. 81

PsiOxus Therapeutics Limited 82

Sanofi 83

Sanofi Pasteur SA 84

Shenzen SiBiono GeneTech Co., Ltd 85

Sotio a.s. 86

Synta Pharmaceuticals Corp. 87

Tesaro, Inc. 88

TetraLogic Pharmaceuticals 89

Tyrogenex, Inc. 90

VentiRx Pharmaceuticals, Inc. 91

Epithelial Ovarian Cancer-Therapeutics Assessment 92

Assessment by Monotherapy Products 92

Assessment by Target 93

Assessment by Mechanism of Action 98

Assessment by Route of Administration 103

Assessment by Molecule Type 105

Drug Profiles 107

abexinostat hydrochloride-Drug Profile 107

abiraterone acetate-Drug Profile 110

ABT-898-Drug Profile 113

alisertib-Drug Profile 114

anetumab ravtansine-Drug Profile 118

Antisense Oligonucleotide for Ovarian and Colorectal Cancer-Drug Profile 120

AT-406-Drug Profile 121

AZD-1775-Drug Profile 124

bevacizumab-Drug Profile 126

bevacizumab biosimilar-Drug Profile 132

bevacizumab biosimilar-Drug Profile 133

bevacizumab biosimilar-Drug Profile 134

bevacizumab biosimilar-Drug Profile 135

bevacizumab biosimilar-Drug Profile 136

bevacizumab biosimilar-Drug Profile 137

bevacizumab biosimilar-Drug Profile 138

bevacizumab biosimilar-Drug Profile 139

bevacizumab biosimilar-Drug Profile 140

birinapant-Drug Profile 141

BNC-105-Drug Profile 144

cabozantinib s-malate-Drug Profile 146

CDX-1401-Drug Profile 150

Cell Therapy to Target NY-ESO-1 for Oncology-Drug Profile 152

cositecan-Drug Profile 154

CRLX-101-Drug Profile 156

CVac-Drug Profile 159

dalantercept-Drug Profile 162

DCVAC/OvCa-Drug Profile 164

DMUC-4064A-Drug Profile 165

E-7046-Drug Profile 166

elesclomol-Drug Profile 167

eltrapuldencel-T-Drug Profile 169

enadenotucirev-Drug Profile 172

epacadostat-Drug Profile 174

erismodegib-Drug Profile 176

fosbretabulin tromethamine-Drug Profile 179

ganetespib-Drug Profile 183

GEN-1-Drug Profile 187

Gene Therapy to Activate p53 for Oncology-Drug Profile 190

guadecitabine-Drug Profile 191

IMT-1012-Drug Profile 195

LCL-161-Drug Profile 196

lifastuzumab vedotin-Drug Profile 198

lurbinectedin-Drug Profile 200

MesoCART-Drug Profile 203

mirvetuximab soravtansine-Drug Profile 204

MIS-416-Drug Profile 206

motolimod-Drug Profile 209

MV-NIS-Drug Profile 211

NERX-313E-Drug Profile 213

NERX-505X-Drug Profile 214

nintedanib-Drug Profile 216

niraparib-Drug Profile 221

NSC-748933-Drug Profile 223

OBI-822/821-Drug Profile 224

olaratumab-Drug Profile 226

Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology-Drug Profile 228

OPB-111001-Drug Profile 230

paclitaxel-Drug Profile 231

PankoMab-GEX-Drug Profile 233

pelareorep-Drug Profile 234

pembrolizumab-Drug Profile 239

PF-06647263-Drug Profile 248

prexasertib-Drug Profile 249

Procure-Drug Profile 251

Protein to Antagonize Frizzled Receptors for Epithelial Ovarian Cancer-Drug Profile 252

ralimetinib mesylate-Drug Profile 253

regorafenib-Drug Profile 254

rucaparib phosphate-Drug Profile 258

SAR-408701-Drug Profile 261

SC-003-Drug Profile 262

Stem Cell Therapy to Activate Interferon Beta for Epithelial Ovarian Cancer-Drug Profile 263

trabectedin-Drug Profile 264

trebananib-Drug Profile 269

tremelimumab-Drug Profile 272

TroVax-Drug Profile 275

Vaccine for Oncology-Drug Profile 278

Vaccine to Target Cellular Tumor Antigen p53 for Oncology-Drug Profile 279

Vaccine to Target IGFBP-2 for Epithelial Ovarian Cancer-Drug Profile 280

varlilumab-Drug Profile 281

VCP-2292-Drug Profile 283

veliparib-Drug Profile 284

X-82-Drug Profile 288

Epithelial Ovarian Cancer-Recent Pipeline Updates 290

Epithelial Ovarian Cancer-Dormant Projects 434

Epithelial Ovarian Cancer-Discontinued Products 437

Epithelial Ovarian Cancer-Product Development Milestones 438

Featured News & Press Releases 438

Appendix 443

Methodology 443

Coverage 443

Secondary Research 443

Primary Research 443

Expert Panel Validation 443

Contact Us 443

Disclaimer 444

List of Tables

Number of Products under Development for Epithelial Ovarian Cancer, H2 2015 18

Number of Products under Development for Epithelial Ovarian Cancer-Comparative Analysis, H2 2015 19

Number of Products under Development by Companies, H2 2015 21

Number of Products under Development by Companies, H2 2015 (Contd..1) 22

Number of Products under Development by Companies, H2 2015 (Contd..2) 23

Number of Products under Development by Companies, H2 2015 (Contd..3) 24

Number of Products under Development by Companies, H2 2015 (Contd..4) 25

Number of Products under Investigation by Universities/Institutes, H2 2015 26

Comparative Analysis by Late Stage Development, H2 2015 27

Comparative Analysis by Clinical Stage Development, H2 2015 28

Comparative Analysis by Early Stage Development, H2 2015 29

Products under Development by Companies, H2 2015 30

Products under Development by Companies, H2 2015 (Contd..1) 31

Products under Development by Companies, H2 2015 (Contd..2) 32

Products under Development by Companies, H2 2015 (Contd..3) 33

Products under Development by Companies, H2 2015 (Contd..4) 34

Products under Development by Companies, H2 2015 (Contd..5) 35

Products under Investigation by Universities/Institutes, H2 2015 36

Epithelial Ovarian Cancer-Pipeline by AbbVie Inc., H2 2015 37

Epithelial Ovarian Cancer-Pipeline by Acceleron Pharma, Inc., H2 2015 38

Epithelial Ovarian Cancer-Pipeline by Adaptimmune Limited, H2 2015 39

Epithelial Ovarian Cancer-Pipeline by Amgen Inc., H2 2015 40

Epithelial Ovarian Cancer-Pipeline by Ascenta Therapeutics, Inc., H2 2015 41

Epithelial Ovarian Cancer-Pipeline by Astex Pharmaceuticals, Inc., H2 2015 42

Epithelial Ovarian Cancer-Pipeline by AstraZeneca Plc, H2 2015 43

Epithelial Ovarian Cancer-Pipeline by Bayer AG, H2 2015 44

Epithelial Ovarian Cancer-Pipeline by Bionomics Limited, H2 2015 45

Epithelial Ovarian Cancer-Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2015 46

Epithelial Ovarian Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2015 47

Epithelial Ovarian Cancer-Pipeline by Caladrius Biosciences, Inc. , H2 2015 48

Epithelial Ovarian Cancer-Pipeline by Celldex Therapeutics, Inc., H2 2015 49

Epithelial Ovarian Cancer-Pipeline by Celon Pharma Sp. z o.o., H2 2015 50

Epithelial Ovarian Cancer-Pipeline by Celsion Corporation, H2 2015 51

Epithelial Ovarian Cancer-Pipeline by Cerulean Pharma, Inc., H2 2015 52

Epithelial Ovarian Cancer-Pipeline by Clovis Oncology, Inc., H2 2015 53

Epithelial Ovarian Cancer-Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 54

Epithelial Ovarian Cancer-Pipeline by EirGenix Inc., H2 2015 55

Epithelial Ovarian Cancer-Pipeline by Eisai Co., Ltd., H2 2015 56

Epithelial Ovarian Cancer-Pipeline by Eli Lilly and Company, H2 2015 57

Epithelial Ovarian Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 58

Epithelial Ovarian Cancer-Pipeline by Exelixis, Inc., H2 2015 59

Epithelial Ovarian Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 60

Epithelial Ovarian Cancer-Pipeline by Genentech, Inc., H2 2015 61

Epithelial Ovarian Cancer-Pipeline by Genor BioPharma Co., Ltd., H2 2015 62

Epithelial Ovarian Cancer-Pipeline by Glycotope GmbH, H2 2015 63

Epithelial Ovarian Cancer-Pipeline by Hetero Drugs Limited, H2 2015 64

Epithelial Ovarian Cancer-Pipeline by ImmunoGen, Inc., H2 2015 65

Epithelial Ovarian Cancer-Pipeline by Immunotope, Inc., H2 2015 66

Epithelial Ovarian Cancer-Pipeline by Incyte Corporation, H2 2015 67

Epithelial Ovarian Cancer-Pipeline by Innate Immunotherapeutics Limited, H2 2015 68

Epithelial Ovarian Cancer-Pipeline by Johnson & Johnson, H2 2015 69

Epithelial Ovarian Cancer-Pipeline by Mabion SA, H2 2015 70

Epithelial Ovarian Cancer-Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015 71

Epithelial Ovarian Cancer-Pipeline by MedImmune, LLC, H2 2015 72

Epithelial Ovarian Cancer-Pipeline by Merck & Co., Inc., H2 2015 73

Epithelial Ovarian Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 74

Epithelial Ovarian Cancer-Pipeline by Mycenax Biotech Inc., H2 2015 75

Epithelial Ovarian Cancer-Pipeline by Novartis AG, H2 2015 76

Epithelial Ovarian Cancer-Pipeline by Oasmia Pharmaceutical AB, H2 2015 77

Epithelial Ovarian Cancer-Pipeline by OBI Pharma, Inc., H2 2015 78

Epithelial Ovarian Cancer-Pipeline by Oncobiologics, Inc., H2 2015 79

Epithelial Ovarian Cancer-Pipeline by Oncolytics Biotech Inc., H2 2015 80

Epithelial Ovarian Cancer-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 81

Epithelial Ovarian Cancer-Pipeline by Oxford BioMedica Plc, H2 2015 82

Epithelial Ovarian Cancer-Pipeline by OXiGENE, Inc., H2 2015 83

Epithelial Ovarian Cancer-Pipeline by Pfizer Inc., H2 2015 84

Epithelial Ovarian Cancer-Pipeline by Pharma Mar, S.A., H2 2015 85

Epithelial Ovarian Cancer-Pipeline by Pharmacyclics, Inc., H2 2015 86

Epithelial Ovarian Cancer-Pipeline by Prima BioMed Ltd., H2 2015 87

Epithelial Ovarian Cancer-Pipeline by PsiOxus Therapeutics Limited, H2 2015 88

Epithelial Ovarian Cancer-Pipeline by Sanofi, H2 2015 89

Epithelial Ovarian Cancer-Pipeline by Sanofi Pasteur SA, H2 2015 90

Epithelial Ovarian Cancer-Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015 91

Epithelial Ovarian Cancer-Pipeline by Sotio a.s., H2 2015 92

Epithelial Ovarian Cancer-Pipeline by Synta Pharmaceuticals Corp., H2 2015 93

Epithelial Ovarian Cancer-Pipeline by Tesaro, Inc., H2 2015 94

Epithelial Ovarian Cancer-Pipeline by TetraLogic Pharmaceuticals, H2 2015 95

Epithelial Ovarian Cancer-Pipeline by Tyrogenex, Inc., H2 2015 96

Epithelial Ovarian Cancer-Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015 97

Assessment by Monotherapy Products, H2 2015 98

Number of Products by Stage and Target, H2 2015 100

Number of Products by Stage and Mechanism of Action, H2 2015 105

Number of Products by Stage and Route of Administration, H2 2015 110

Number of Products by Stage and Molecule Type, H2 2015 112

Epithelial Ovarian Cancer Therapeutics-Recent Pipeline Updates, H2 2015 296

Epithelial Ovarian Cancer-Dormant Projects, H2 2015 440

Epithelial Ovarian Cancer-Dormant Projects (Contd..1), H2 2015 441

Epithelial Ovarian Cancer-Dormant Projects (Contd..2), H2 2015 442

Epithelial Ovarian Cancer-Discontinued Products, H2 2015 443

List of Figures

Number of Products under Development for Epithelial Ovarian Cancer, H2 2015 18

Number of Products under Development for Epithelial Ovarian Cancer-Comparative Analysis, H2 2015 19

Number of Products under Development by Companies, H2 2015 20

Number of Products under Investigation by Universities/Institutes, H2 2015 26

Comparative Analysis by Clinical Stage Development, H2 2015 28

Comparative Analysis by Early Stage Products, H2 2015 29

Assessment by Monotherapy Products, H2 2015 98

Number of Products by Top 10 Targets, H2 2015 99

Number of Products by Stage and Top 10 Targets, H2 2015 99

Number of Products by Top 10 Mechanism of Actions, H2 2015 104

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 104

Number of Products by Top 10 Routes of Administration, H2 2015 109

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 109

Number of Products by Top 10 Molecule Types, H2 2015 111

Number of Products by Stage and Top 10 Molecule Types, H2 2015 111

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Acceleron Pharma, Inc.

Adaptimmune Limited

Amgen Inc.

Ascenta Therapeutics, Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Bayer AG

Bionomics Limited

BioNumerik Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Caladrius Biosciences, Inc.

Celldex Therapeutics, Inc.

Celon Pharma Sp. z o.o.

Celsion Corporation

Cerulean Pharma, Inc.

Clovis Oncology, Inc.

Dr. Reddy's Laboratories Limited

EirGenix Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Genor BioPharma Co., Ltd.

Glycotope GmbH

Hetero Drugs Limited

ImmunoGen, Inc.

Immunotope, Inc.

Incyte Corporation

Innate Immunotherapeutics Limited

Johnson & Johnson

Mabion SA

MabVax Therapeutics Holdings, Inc.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

Mycenax Biotech Inc.

Novartis AG

Oasmia Pharmaceutical AB

OBI Pharma, Inc.

Oncobiologics, Inc.

Oncolytics Biotech Inc.

Otsuka Holdings Co., Ltd.

Oxford BioMedica Plc

OXiGENE, Inc.

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Prima BioMed Ltd.

PsiOxus Therapeutics Limited

Sanofi

Sanofi Pasteur SA

Shenzen SiBiono GeneTech Co., Ltd

Sotio a.s.

Synta Pharmaceuticals Corp.

Tesaro, Inc.

TetraLogic Pharmaceuticals

Tyrogenex, Inc.

VentiRx Pharmaceuticals, Inc.

Epithelial Ovarian Cancer Therapeutic Products under Development, Key Players in Epithelial Ovarian Cancer Therapeutics, Epithelial Ovarian Cancer Pipeline Overview, Epithelial Ovarian Cancer Pipeline, Epithelial Ovarian Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com